Overview
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive mature T-cell leukemia characterized by an accumulation of prolymphocytes in the peripheral blood, often with systemic involvement 1.Diagnosis
Key Diagnostic Criteria: Hyperlymphocytosis with prolymphocytes, immunophenotype typically showing TdT-, CD2+, CD5+, CD3+, and CD7+ 1.
Recommended Tests: Cytological examination, flow cytometry for immunophenotyping, and molecular studies to confirm diagnosis 1.Management
First-Line Treatment: Intensive chemotherapy regimens such as 2'-deoxycoformycin (dCF) or pentostatin are favored due to T-PLL's refractoriness to conventional therapies 1.
Specific Doses/Drugs: Pentostatin administered weekly for 1 month followed by maintenance therapy for 6 months has been used in specific contexts 1.
Adjunctive Treatments: Consideration of anti-CDw52 monoclonal antibodies in conjunction with chemotherapy, though specific dosing details are not provided 1.Special Populations
Immunodeficiency Context: In patients with underlying immunodeficiencies like Nijmegen breakage syndrome, treatment approaches may need to be tailored to address concurrent issues such as hemolytic anemia and clotting factor deficiencies 1.Key Recommendations
Initiate intensive chemotherapy with agents like pentostatin for treatment of T-PLL, especially in refractory cases (Evidence: Weak) 1.
Consider adjunctive therapies targeting specific complications, such as autoimmune manifestations or coagulation disorders, based on individual patient needs (Evidence: Expert opinion) 1.
Monitor and manage concurrent immunodeficiencies and associated complications during treatment, adapting therapy accordingly (Evidence: Expert opinion) 1.References
1 Michallet AS, Lesca G, Radford-Weiss I, Delarue R, Varet B, Buzyn A. T-cell prolymphocytic leukemia with autoimmune manifestations in Nijmegen breakage syndrome. Annals of hematology 2003. link